Mosaic ImmunoEngineering Inc. (OTCQB:CPMV) announced that Nicole F. Steinmetz, Ph.D., will present at the World Molecular Imaging Congress virtually on October 8, 2021. The presentation will cover the preclinical data of Mosaic's MIE-101, a plant virus-based cancer immunotherapy, and developments in its Modular Vaccine Platform for COVID-19. The company's core technology utilizes Cowpea mosaic virus to elicit immune responses against tumors. The event will focus on tracking viruses and vaccines in the context of COVID-19.
Mosaic ImmunoEngineering has showcased a novel polymer-based delivery system for vaccines, offering a potential solution that may eliminate the need for booster shots. Highlighted in a keynote by co-founder Jon Pokorski at the American Society for Composites conference, this system is noted for its room temperature stability and ease of storage, facilitating single-dose treatments. CEO Steven King emphasized the technology's rapid development capability and its effectiveness against various diseases, including SARS-CoV-2, positioning the company favorably in the biotech landscape.
Mosaic ImmunoEngineering Inc. (OTCQB:CPMV) has published preclinical data illustrating high efficacy of its Modular Vaccine Platform (MVP) against SARS-CoV-2 and SARS-CoV-1, demonstrating robust neutralizing antibody production in animal models. The vaccine candidates, stable at room temperature and administered as single doses, target non-mutating epitopes, offering resilience against variants like Delta. Funded by the National Science Foundation, Mosaic aims to expand this technology for COVID-19 and other viral diseases, while pursuing strategic partnerships and government grants for broader research.
Mosaic ImmunoEngineering Inc. (OTCQB:CPMV) has licensed novel vaccine candidates from UC San Diego aimed at addressing SARS-CoV-2 and other infectious diseases.
The Modular Vaccine Platform (MVP) utilizes protein nanoparticle-based adjuvants combined with targeted peptides for effective immune response. This technology allows rapid vaccine development, demonstrating potential for self-administration and room-temperature stability.
Federal grants funding and peer-reviewed publications support the efficacy of these vaccine candidates.
Mosaic ImmunoEngineering (OTCQB:CPMV) announced significant findings regarding its lead immuno-oncology candidate, MIE-101, showing an 80% reduction in tumor growth in preclinical studies. The research published in Biomaterials demonstrated that MIE-101 activates three Toll-like receptors (TLRs 2, 4, and 7), enhancing immune activation and antitumor effects. Prominent results indicate that MIE-101 outperforms single TLR-targeting agents. The company aims to submit an Investigational New Drug (IND) application in 2022, further advancing its mission to develop effective cancer therapies.
Mosaic ImmunoEngineering Inc. (OTCQB:CPMV) announced its application for listing on the Nasdaq Capital Market. The approval is subject to Nasdaq's review and compliance with its regulations. The company aims to enhance investor visibility, increase trading liquidity, and drive shareholder value. Mosaic specializes in immunotherapies using Cowpea Mosaic Virus (CPMV) technology, targeting cancer and infectious diseases. The research is supported by various grants and collaborations, including ongoing studies for potential vaccines against COVID-19.
Mosaic ImmunoEngineering Inc. (OTCQB:CPMV) has appointed Dr. Robert A. Baffi to its Board of Directors, enhancing its leadership with over three decades of industry experience. Previously President of Global Manufacturing at BioMarin Pharmaceutical, Dr. Baffi is recognized for his expertise in virus-based therapeutics and drug development, overseeing over 50 regulatory submissions. Mosaic focuses on immunotherapy solutions targeting cancer and infectious diseases, utilizing the non-infectious Cowpea Mosaic Virus (CPMV) platform. The appointment is expected to strengthen Mosaic's strategic direction and product development capabilities.